ArticleInternational journal of clinical pharmacy2025

Cost-effectiveness analysis of PD-L1 testing associated with pembrolizumab for first-line treatment of advanced non-small cell lung cancer in China.

Yao Wu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.